{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:29:17Z","timestamp":1772224157910,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.2165\/11636020-000000000-00000","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T21:18:13Z","timestamp":1362518293000},"page":"177-185","source":"Crossref","is-referenced-by-count":8,"title":["Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections"],"prefix":"10.1007","volume":"12","author":[{"given":"Yoshiko","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiemi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Kunihiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,23]]},"reference":[{"key":"12040177_CR1","unstructured":"Cravit\u00ae ophthalmic solution: prescribing information. Osaka: Santen Pharmaceutical Co., Ltd., 2005 Oct"},{"issue":"12","key":"12040177_CR2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1517\/14656566.8.12.1903","volume":"8","author":"P Rose","year":"2007","unstructured":"Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007 Aug; 8(12): 1903\u201321","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"12040177_CR3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.32.9.1336","volume":"32","author":"T Une","year":"1988","unstructured":"Une T, Fujimoto T, Sato K, et al. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988 Sep; 32(9): 1336\u201340","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"12040177_CR4","first-page":"1113","volume":"14","author":"M Usui","year":"1997","unstructured":"Usui M. Clinical evaluation of levofloxacin ophthalmic solution: phase III open label trial [in Japanese]. Atarashii Ganka 1997; 14(7): 1113\u20138","journal-title":"Atarashii Ganka"},{"issue":"4","key":"12040177_CR5","first-page":"641","volume":"14","author":"M Usui","year":"1997","unstructured":"Usui M. Clinical evaluation of levofloxacin ophthalmic solution: a multicenter phase III double-masked clinical trial [in Japanese]. Atarashii Ganka 1997; 14(4): 641\u20138","journal-title":"Atarashii Ganka"},{"key":"12040177_CR6","first-page":"299","volume":"14","author":"M Usui","year":"1997","unstructured":"Usui M. Clinical evaluation of levofloxacin ophthalmic solution: a multicenter phase II double-masked clinical trial [in Japanese]. Atarashii Ganka 1997; 14: 299\u2013307","journal-title":"Atarashii Ganka"},{"issue":"6","key":"12040177_CR7","first-page":"953","volume":"14","author":"M Usui","year":"1997","unstructured":"Usui M. Effect of levofloxacin ophthalmic solution on preoperative sterilization [in Japanese]. Atarashii Ganka 1997; 14(6): 953\u20136","journal-title":"Atarashii Ganka"},{"key":"12040177_CR8","unstructured":"Quixin\u00ae (levofloxacin ophthalmic solution) 0.5%: prescribing information [online]. Available from URL: http:\/\/www.quixin.com\/ [Accessed 2012 May 22]"},{"key":"12040177_CR9","unstructured":"Santen Pharmaceutical Co., Ltd. Products in Europe [online]. Available from URL: http:\/\/www.santen.eu\/eu\/products\/Pages\/default.aspx [Accessed 2012 May 22]"},{"key":"12040177_CR10","volume-title":"Ministerial ordinance on good post-marketing surveillance practice (GPMSP) no. 10","author":"Ministry of Health, LabourWelfare","year":"1997","unstructured":"Ministry of Health, Labour and Welfare. Ministerial ordinance on good post-marketing surveillance practice (GPMSP) no. 10. Tokyo: Ministry of Health, Labour and Welfare, 1997 Mar 3"},{"key":"12040177_CR11","series-title":"notification no. 34","volume-title":"Guidelines on methods of clinical use result surveys on ethical drugs","author":"PharmaceuticalFood Safety Bureau, Ministry of Health, LabourWelfare","year":"1997","unstructured":"Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Guidelines on methods of clinical use result surveys on ethical drugs (notification no. 34). Tokyo: Ministry of Health, Labour and Welfare, 1997 Mar 27"},{"key":"12040177_CR12","unstructured":"Santen Pharmaceutical Co., Ltd. Tarivid\u00ae ophthalmic solution 0.3% (ofloxacin ophthalmic solution): interview form [online]. Available from URL: http:\/\/www.santen.co.jp\/medical\/common\/pdf\/info_package\/if\/tarivid.pdf [Accessed 2012 May 22]"},{"key":"12040177_CR13","unstructured":"Senju Pharmaceutical Co., Ltd. Lomeflon\u00ae ophthalmic solution 0.3% (lomefloxacin ophthalmic solution): interview form [online]. Available from URL: http:\/\/www.senju.co.jp\/medical\/products\/_icsFiles\/afieldfile\/2011\/09\/26\/rm.pdf [Accessed 2012 May 22]"},{"key":"12040177_CR14","unstructured":"Nichi-Iko Pharmaceutical Co., Ltd. Noflo\u00ae ophthalmic solution 0.3% (norfloxacin ophthalmic solution 0.3%): package insert [online]. Available from URL: http:\/\/www.info.pmda.go.jp\/go\/pack\/1319727Q1158_2_02\/ [Accessed 2012 May 22]"},{"key":"12040177_CR15","first-page":"1419","volume":"21","author":"K Oshima","year":"2004","unstructured":"Oshima K, Kojima C, Sawada S, et al. Postmarketing survey of ibudilast (Eyevinal\u00ae) ophthalmic solution in allergic conjunctivitis: drug use results survey [in Japanese]. Atarashii Ganka 2004; 21: 1419\u201327","journal-title":"Atarashii Ganka"},{"key":"12040177_CR16","first-page":"431","volume":"19","author":"K Matsuzaki","year":"2003","unstructured":"Matsuzaki K, Koyama H, Watanabe E, et al. Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to levofloxacin and other antimicrobial drugs [in Japanese]. Antibiotics & Chemotherapy 2003; 19: 431\u201340","journal-title":"Antibiotics & Chemotherapy"},{"issue":"11","key":"12040177_CR17","first-page":"1539","volume":"21","author":"K Matsuzaki","year":"2004","unstructured":"Matsuzaki K, Watanabe E, Shikano M, et al. Susceptibility of ocular infection isolates to levofloxacin and other antimicrobial drugs [in Japanese]. Atarashii Ganka 2004; 21(11): 1539\u201346","journal-title":"Atarashii Ganka"},{"issue":"2","key":"12040177_CR18","first-page":"237","volume":"23","author":"I Kobayashi","year":"2006","unstructured":"Kobayashi I, Matsuzaki K, Shitou K, et al. Surveillance of ocular infection isolate susceptibility to levofloxacin and other antimicrobial drugs [in Japanese]. Atarashii Ganka 2006; 23(2): 237\u201343","journal-title":"Atarashii Ganka"},{"key":"12040177_CR19","first-page":"801","volume":"21","author":"A Kakimaru","year":"2004","unstructured":"Kakimaru A, Kawaguchi A, Mihara E. Suture abscess of levofloxacin-resistant Corynebacterium spp. [in Japanese]. Atarashii Ganka 2004; 21: 801\u20134","journal-title":"Atarashii Ganka"},{"issue":"3","key":"12040177_CR20","first-page":"511","volume":"90","author":"Y Mitsui","year":"1986","unstructured":"Mitsui Y, Kitano S, Uchida Y, et al. Standardization of the evaluation of antimicrobial ophthalmic solutions and ointments, 1985 [in Japanese]. Nippon Ganka Gakkai Zasshi 1986; 90(3): 511\u20135","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"12040177_CR21","first-page":"138","volume-title":"Ocular infections clinic","author":"K Kameyama","year":"2000","unstructured":"Kameyama K. Dacryocystitis. In: Usui M, Ohashi Y, Tagawa Y, et al., editors. Ocular infections clinic [in Japanese]. Tokyo: Igaku-shoin Ltd., 2000: 138\u20139"},{"key":"12040177_CR22","first-page":"769","volume":"111","author":"Japanese Association for Ocular Infection","year":"2007","unstructured":"Japanese Association for Ocular Infection. Guidelines for the clinical management of infectious keratitis [in Japanese]. Nippon Ganka Gakkai Zasshi 2007; 111: 769\u2013809","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"13","key":"12040177_CR23","first-page":"2007","volume":"62","author":"Y Kanda","year":"2008","unstructured":"Kanda Y, Kayama T, Okamoto S, et al. A post-marketing surveillance of 0.5% levofloxacin ophthalmic solution for external ocular infections. Rinsho Ganka 2008; 62(13): 2007\u201317","journal-title":"Rinsho Ganka"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2165\/11636020-000000000-00000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T08:48:16Z","timestamp":1498034896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/11636020-000000000-00000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["12040177"],"URL":"https:\/\/doi.org\/10.2165\/11636020-000000000-00000","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}